Triple-negative breast cancer (TNBC) is an aggressive and heterogeneous disease that represents about 15% of breast cancer cases. Classified as…
featured news
Peptomyc has received full study approval for its Phase Ib clinical trial evaluating the combination of its first-in-class MYC inhibitor…
Published in the journal Clinical Cancer Research (1), preliminary results of a two-part, phase I first-in-human study show encouraging antitumor…
Mutations in the TP53 tumor suppressor gene occur in 50% of lung adenocarcinoma and associate with a poor prognosis, but…
Published in The Lancet Oncology (1) and co-authored by VHIO’s Cristina Suarez, results from the single-arm phase II KEYNOTE-B61 clinical…
We are delighted to announce that VHIO’s Rodrigo Dienstmann has been appointed as Editor-in-Chief of the European Society for Medical…
Recently published open access in the journal Nature Communications*, an invited Comment article first authored by VHIO’s Elena Garralda, sets…
Blood-based circulating tumor DNA analysis of plasma samples from patients enrolled in the open-label, randomized phase III VOYAGER clinical trial…
VHIO has participated in this project coordinated by INCLIVA, which has made it possible to expand knowledge about this type…
Results of the study FRESCO-2 show a statistically and clinically meaningful benefit with a favorable safety profile in patients with…
